(vianews) - the market ended the session with ab science (ab.pa) rising 14.34% to €4.15 on thursday, after two sequential sessions in a row of gains. cac 40 rose 0.11% to €7,464.20, following the last session's upward trend on what was a somewhat positive trend trading session today.
ab science's last close was €3.63, 51.6% below its 52-week high of €7.49.
about ab science
ab science s.a., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. its lead compound is the masitinib, a tyrosine kinase inhibitor that is in phase iii clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, alzheimer's, severe asthma, and mastocytosis diseases, as well as in phase ii clinical trial to treat covid-19. the company is also developing ab8939, a synthetic microtubule destabiliser for haematology indications. the company markets its masitinib under the masivet brand in europe. ab science s.a. was incorporated in 2001 and is headquartered in paris, france.
earnings per share
as for profitability, ab science has a trailing twelve months eps of €-0.36.
more news about ab science (ab.pa).